Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10637-021-01076-8.pdf
Reference25 articles.
1. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K (1997) Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3:47–50
2. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ (2010) Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65(Suppl 2):ii32–i40. https://doi.org/10.1136/thx.2010.136994
3. Yoshida K, Sugiura T, Takifuji N, Kawahara M, Matsui K, Kudoh S, Takada M, Fukuoka M, Ariyoshi Y, Fukuda H, Saijo N (2007) Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 58:362–368. https://doi.org/10.1016/j.lungcan.2007.07.009
4. Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S (2018) Sterilized talc pleurodesis for malignant pleural effusions: a phase II study for investigational new drug application in Japan. Jpn J Clin Oncol 48:376–381. https://doi.org/10.1093/jjco/hyy020
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. https://doi.org/10.1056/NEJMoa061884
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?;Investigational New Drugs;2024-02-22
2. Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion;BMC Pulmonary Medicine;2024-02-16
3. First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?;2023-09-27
4. A Case of ALK-rearranged Lung Cancer with a Durable Response to Atezolizumab Plus Bevacizumab/Carboplatin/Paclitaxel Combination Therapy After Initial Resistance to Alectinib;Haigan;2023-06-20
5. Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting;Anticancer Research;2023-02-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3